EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?

EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?

Epidermal growth factor receptor-tyrosine-kinase inhibitors (EGFR-TKIs) brought a significant revolution in the treatment of non-small-cell lung cancer (NSCLC). In a short period of time, EGFR-TKIs became the standard of treatment for mutation-positive, advanced stage non-squamous NSCLC. In recent y...

Full description

Bibliographic Details
Main Authors: Milovancev, Aleksandar, Stojsic, Vladimir, Zaric, Bojan, Kovacevic, Tomi, Sarcev, Tatjana, Perin, Branislav, Zarogoulidis, Konstantinos, Tsirgogianni, Katerina, Freitag, Lutz, Darwiche, Kaid, Tsavlis, Drosos, Zissimopoulos, Athanasios, Stratakos, Grigoris, Zarogoulidis, Paul
Format: Online
Language:English
Published: Dove Medical Press 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610780/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4610780/

Similar Items